Dr Reddy’s Laboratories launches cancer treatment drug Capecitabine in US

The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration

PTI
Updated17 Feb 2021, 12:22 PM IST
Shares of Dr Reddy's Laboratories were trading 0.98% lower at  <span class='webrupee'>₹</span>4,650 apiece on BSE.
Shares of Dr Reddy’s Laboratories were trading 0.98% lower at ₹4,650 apiece on BSE.

Drug major Dr Reddy's Laboratories on Wednesday said it has launched cancer treatment drug Capecitabine tablets in the US market.

The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).

In a regulatory filing, Dr Reddy's laboratories announced launch of Capecitabine tablets in the US.

Also Read  Life lessons from Covidian era startups

Quoting IQVIA Health data, Dr Reddy's said the Xeloda brand and generic had US sales of approximately USD 90 million for the most recent 12 months ending in October 2020.

Dr Reddy's Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Shares of Dr Reddy's Laboratories were trading 0.98% lower at 4,650 apiece on BSE.

Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Business NewsCompaniesNewsDr Reddy’s Laboratories launches cancer treatment drug Capecitabine in US
MoreLess
First Published:17 Feb 2021, 12:19 PM IST
Most Active Stocks
Market Snapshot
  • Top Gainers
  • Top Losers
  • 52 Week High
Recommended For You
    More Recommendations
    Gold Prices
    • 24K
    • 22K
    Fuel Price
    • Petrol
    • Diesel
    Popular in Companies